Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

Publisher： John Wiley & Sons Inc

E-ISSN： 1528-1167|56|8|1252-1263

ISSN： 0013-9580

Source： EPILEPSIA, Vol.56, Iss.8, 2015-08, pp. : 1252-1263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

By  

EPILEPSIA, Vol. 56, Iss. 1, 2015-01 ,pp. : 12-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures

By  

EPILEPSIA, Vol. 56, Iss. 7, 2015-07 ,pp. : e90-e94

John Wiley & Sons Inc

Access to resources Recommend Favorite

Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double‐blind placebo‐controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 3, 2015-03 ,pp. : 754-759

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?

By  

Current Drug Safety, Vol. 8, Iss. 2, 2013-01 ,pp. : 104-113

Bentham Science Publishers

Access to resources Recommend Favorite

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

By  

EPILEPSIA, Vol. 56, Iss. 6, 2015-06 ,pp. : 924-932

John Wiley & Sons Inc

Access to resources Recommend Favorite